The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 340 participants.

Also called NCT07739160

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 340 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07739160
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07739160. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-29 (actual); primary completion 2027-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients
Condition
Acute Ischemic Stroke
Intervention (Drug)
HRS-4029
Intervention (Drug)
Placebo
Lead sponsor
Beijing Suncadia Pharmaceuticals Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct07739160
Content hash
67fd2a05e28497b68e8601e62aae467420fa8befd5450c0edcec16e0eb47d89a